Drug delivery system with scleral lens

• US 20080286338A1
• Filed: 05/15/2007
• Published: 11/20/2008
• Est. Priority Date: 05/15/2007
• Status: Abandoned Application

• Current Assignee: The Boston Foundation for Sight, Inc.
• Original Assignee: The Boston Foundation for Sight, Inc.
• Inventors: Rosenthal, Perry, Jacobs, Deborah S.
• Application Number:
  US11/803,719
• Publication Number:
  US 20080286338A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 2/142 Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue
• CPC Class Codes: A61F 2002/1681 having supporting structure for lens, e.g. haptics
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: G02C 7/04 Contact lenses for the eyes disinfection or sterilisation of contact lenses A61L12/00

Abstract

A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance.

Claims

1. A drug delivery system comprising a drug and a lens disposed on an eye having a back surface comprising:

an optic portion and a scleral portion (haptic), the haptic portion having an outer rim and an inner rim.

2. The drug delivery system of claim 1, wherein the lens is a scleral lens.

3. The drug delivery system of claim 2, wherein the scleral lens contacts only the sclera.

4. The drug delivery system of claim 2, wherein the scleral lens contacts only the sclera and the periphery of the cornea.

5. The drug delivery system of claim 2, wherein the haptic portion of the scleral lens further defines a channel that extends radially at least part of the distance between the outer rim and the inner rim.

6. The drug delivery system of claim 1, wherein the drug is selected from the group consisting of an antibiotic, an antiviral, an antifungal, an antiparasitic, a corticosteroid, a non-steroidal anti-inflammatory, a mydriatic, a biologic, a drug that modifies neovascularization, a drug that increases aqueous outflow, a drug that reduces aqueous secretion, an antihistamine, a secretagogue, a mast cell stabilizer, a tear supplement, an anti-metabolite, and an immunomodulator.

7. The drug delivery system of claim 6, wherein the drug is a biologic.

8. The drug delivery system of claim 7, wherein the drug is a protein.

9. The drug delivery system of claim 8, wherein the drug is an antibody or an antibody fragment.

10. The drug delivery system of claim 9, wherein the antibody or antibody fragment interacts with a vascular endothelial growth factor or a vascular endothelial growth factor receptor.

11. The drug delivery system of claim 10, wherein the antibody or antibody fragment is selected from the group consisting of bevacizumab, pegaptanib, and ranibizumab.

12. The drug delivery system of claim 6, wherein the drug is an antibiotic.

13. The drug delivery system of claim 6, wherein the drug is an antiviral.

14. The drug delivery system of claim 6, wherein the drug is an antifungal.

15. The drug delivery system of claim 6, wherein the drug is an antiparasitic.

16. The drug delivery system of claim 6, wherein the drug is a corticosteroid.

17. The drug delivery system of claim 6, wherein the drug is a non-steroidal anti-inflammatory.

18. The drug delivery system of claim 6, wherein the drug is a mydriatic.

19. The drug delivery system of claim 6, wherein the drug is a drug that modifies neovascularization.

20. The drug delivery system of claim 6, wherein the drug is a drug that increases aqueous outflow.

21. The drug delivery system of claim 6, wherein the drug is a drug that decreases aqueous secretion.

22. The drug delivery system of claim 6, wherein the drug is an antihistamine.

23. The drug delivery system of claim 6, wherein the drug is a secretagogue.

24. The drug delivery system of claim 6, wherein the drug is a mast cell stabilizer.

25. The drug delivery system of claim 6, wherein the drug is a tear supplement.

26. The drug delivery system of claim 6, wherein the drug is an anti-metabolite.

27. The drug delivery system of claim 6, wherein the drug is an immunomodulator.

28. The drug delivery system of claim 1, where the lens is an optically corrective lens.

29. The drug delivery system of claim 1, where the lens is not an optically corrective lens.

30. The drug delivery system of claim 5, wherein the disease is selected from the group consisting of bacterial infection, viral infection, fungal infection, parasitic infection, inflammation, neovascularization, ocular surface disease, glaucoma, allergy, dry eye, dysplasia, and neoplasm.

31. The drug delivery system of claim 30, wherein the disease is bacterial infection.

32. The drug delivery system of claim 30, wherein the disease is viral infection.

33. The drug delivery system of claim 30, wherein the disease is fungal infection.

34. The drug delivery system of claim 30, wherein the disease is parasitic infection.

35. The drug delivery system of claim 30, wherein the disease is inflammation.

36. The drug delivery system of claim 30, wherein the disease is neovascularization.

37. The drug delivery system of claim 30, wherein the disease is ocular surface disease.

38. The drug delivery system of claim 30, wherein the disease is glaucoma.

39. The drug delivery system of claim 30, wherein the disease is allergy.

40. The drug delivery system of claim 30, wherein the disease is dry eye.

41. The drug delivery system of claim 30, wherein the disease is dysplasia.

42. The drug delivery system of claim 30, wherein the disease is neoplasm.